HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content Social Bookmarking                What's this?

Diabetic Nephropathy

	INTRODUCTION

 
Diabetes has become the most common single cause of end-stage renal disease (ESRD) in the U.S. and Europe; this is due to the facts that 1) diabetes, particularly type 2, is increasing in prevalence; 2) diabetes patients now live longer; and 3) patients with diabetic ESRD are now being accepted for treatment in ESRD programs where formerly they had been excluded. In the U.S., diabetic nephropathy accounts for about 40% of new cases of ESRD, and in 1997, the cost for treatment of diabetic patients with ESRD was in excess of $15.6 billion. About 20–30% of patients with type 1 or type 2 diabetes develop evidence of nephropathy, but in type 2 diabetes, a considerably smaller fraction of these progress to ESRD. However, because of the much greater prevalence of type 2 diabetes, such patients constitute over half of those diabetic patients currently starting on dialysis. There is considerable racial/ethnic variability in this regard, with Native Americans, Hispanics (especially Mexican-Americans), and African-Americans having much higher risks of developing ESRD than non-Hispanic whites with type 2 diabetes. Recent studies have now demonstrated that the onset and course of diabetic nephropathy can be ameliorated to a very significant degree by several interventions, but these interventions have their greatest impact if instituted at a point very early in the course of the development of this complication. This position statement is based on recent review articles that discuss published research and issues that remain unresolved and provides recommendations regarding the detection, prevention, and treatment of early nephropathy.

	NATURAL HISTORY OF DIABETIC NEPHROPATHY

 
The earliest clinical evidence of nephropathy is the appearance of low but abnormal levels ( 30 mg/day or 20 µg/min) of albumin in the urine, referred to as microalbuminuria, and patients with microalbuminuria are referred to as having incipient nephropathy. Without specific interventions, 80% . . . [Full Text of this Article]

	SCREENING FOR ALBUMINURIA

 

	EFFECT OF GLYCEMIC CONTROL

 

	HYPERTENSION CONTROL

 

	USE OF ANTIHYPERTENSIVE AGENTS

 

	PROTEIN RESTRICTION

 

	OTHER ASPECTS OF TREATMENT

 
General recommendations
A-Level evidence
Screening
Expert consesus
Treatment
A-Level evidence
B-Level evidence
Expert consensus

	SUMMARY

 

	Footnotes

 

	Bibliography

 

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J N Harvey Diabetic nephropathy BMJ, July 13, 2002; 325(7355): 59 - 60. [Full Text] [PDF]